Clinical Trial Update: Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study [NA]

View source ↗

Summary

Endogenex announces continued access to its Endogenex System for participants in the ReCET pivotal study, which is not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Endogenex System

Snippet

Sponsor: Endogenex, Inc. | Conditions: Type 2 Diabetes Mellitus, Type2diabetes | NA | Status: NOT_YET_RECRUITING